Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.96 - $42.75 $3.06 Million - $3.36 Million
78,576 New
78,576 $3.21 Million
Q4 2022

Feb 14, 2023

BUY
$25.35 - $31.96 $341,996 - $431,172
13,491 New
13,491 $425,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Y Intercept (Hong Kong) LTD Portfolio

Follow Y Intercept (Hong Kong) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.